NCT07694297尚未招募2 期
A Phase 2, Multicenter, Open-label Study to Evaluate Safety and Efficacy of 500 mg BID NTZ on Top of Standard of Care in Patients With Inflammatory Phenotype Presenting Either With Acute Decompensation of Liver Cirrhosis at High Risk of Progression to Acute-on-Chronic Liver Failure or Established Acute-on-Chronic Liver Failure (CONTROL-ACLF)
Genfit0 个研究点目标入组 16 人开始时间: 2026年10月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 16
- 主要终点
- To evaluate the safety of 500 mg BID NTZ administered perorally
研究概览
简要总结
Phase 2 Study of 500 mg BID NTZ on Top of Standard of Care in Patients with Acute Decompensation of Liver Cirrhosis at High Risk of Progression to Acute-on-Chronic Liver Failure or Established Acute-on-Chronic Liver Failure
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 74 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants are eligible to be included in the study only if all of the following criteria apply:
- •Participants with liver cirrhosis of any underlying etiology (liver cirrhosis diagnosed by standard clinical criteria, imaging findings, and/or histology)
- •Recent acute clinical deterioration within 10 days prior to Day 1 defined as the onset of ascites, HE, gastrointestinal bleeding, or any combination of them with or without infection with or without organ failure
- •Adult male or female participants, defined as having reached the legal age of majority according to local regulations, aged <75 years on the day of signing informed consent form (ICF)
- •Participants or legal representative willing and able to provide written informed consent in accordance with local ethical and legal requirements
- •Participants able to swallow peroral medication
排除标准
- •Participants are excluded from the study if any of the following criteria apply:
- •Known hypersensitivity to nitazoxanide or any known excipient of the IMP
- •Nitazoxanide use within 30 days prior to SCR
- •Uncontrolled acute bleeding at SCR or Day 1
- •Participants with poorly controlled seizure disorder
- •Severe circulatory failure requiring the use of high dose vasopressors (eg, dopamine >15 μg/kg/min, or epinephrine >0.1 μg/kg/min, or norepinephrine >0.1 μg/kg/min); the use of terlipressin or low dose norepinephrine to treat hepatorenal syndrome is not an exclusion criterion
- •Uncontrolled severe infection with hemodynamic instability or shock
- •Need for renal replacement therapy (RRT) or any extracorporeal liver support device
- •Any significant disease considered to be potentially detrimental or would preclude the participant from participating in and completing the study as assessed by the PI
- •Individuals for whom the PI deems that study participation would be unsafe or not in the interest of the participant
- •Pregnancy or lactation
- •Participants of childbearing potential and non-sterile male participants who are not willing to use adequate contraception from SCR to 90 days after the final dose of IMP
- •Participation in another interventional clinical study within 30 days of SCR.
结局指标
主要结局
To evaluate the safety of 500 mg BID NTZ administered perorally
时间窗: over 7 days on top of SOC follow-up period up to Day 28.
Safety defined as the incidence, relatedness, and severity (NCI-CTCAE v6.0 grade) of TEAEs including SAEs (comprising the evaluation of vital signs, ECGs, and laboratory parameters).
次要结局
未报告次要终点
研究者
相似试验
尚未招募
2 期
Glofitamab as a Bridge to and/or Consolidation Post Autologous Stem Cell Transplant in Patients With Relapsed B Cell LymphomasNCT07387848American University of Beirut Medical Center40
尚未招募
3 期
A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLCNSCLCNCT07376382CSPC Megalith Biopharmaceutical Co.,Ltd.680
招募中
2 期
Orelabrutinib Combined With Standard Immunochemotherapy With or Without Autologous Hematopoietic Stem Cell Transplantation (Auto-HSCT) for Newly Diagnosed Diffuse Large B-cell Lymphoma (DLBCL)DLBCL - Diffuse Large B Cell LymphomaNCT07680933The Affiliated Hospital of Xuzhou Medical University30
招募中
2 期
Moxibustion for Steroid-Refractory Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell TransplantationGraft-Versus-Host DiseaseNCT07572669Union Hospital, Tongji Medical College, Huazhong University of Science and Technology42
尚未招募
3 期
Global Phase III Randomized Clinical trial in which we are comparing sponsor test drug with Standard care of Chemotherapy SOC when given to Second or Later Line Adult Participants with Advanced Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma.CTRI/2025/02/080588AstraZeneca AB625